Ligand Pharmaceuticals/LGND

$79.93

0.01%
-
1D1W1MYTD1YMAX

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Ticker

LGND

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Davis

Employees

58

Headquarters

Jupiter, United States

LGND Metrics

BasicAdvanced
$1.41B
Market cap
28.35
P/E ratio
$2.81
EPS
1.02
Beta
-
Dividend rate
$1.41B
1.02496
$94.57
$49.24
165.27K
14.148
12.72
0.001
47.614
6.94%
8.29%
7.5%
28.347
10.756
1.998
6.123
-27.13%
680.7%
-11.02%

What the Analysts think about LGND

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
46.13% upside
High $144.00
Low $95.00
$79.93
Current price
$116.80
Average price target

LGND Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
64.41% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$28.1M
-14.33%
Net income
$18.1M
-277.45%
Profit margin
64.41%
-307.17%

LGND Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 108.85%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$2.28
$1.42
$1.02
$1.38
-
Expected
$0.89
$0.64
$0.61
$0.66
$0.83
Surprise
155.03%
121.96%
67.21%
108.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals (LGND) has a market cap of $1.41B as of April 17, 2024.

What is the P/E ratio for Ligand Pharmaceuticals stock?

The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 28.35 as of April 17, 2024.

Does Ligand Pharmaceuticals stock pay dividends?

No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Ligand Pharmaceuticals dividend payment date?

Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.

What is the beta indicator for Ligand Pharmaceuticals?

Ligand Pharmaceuticals (LGND) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Ligand Pharmaceuticals stock price target?

The target price for Ligand Pharmaceuticals (LGND) stock is $116.8, which is 46.13% above the current price of $79.93. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ligand Pharmaceuticals stock

Buy or sell Ligand Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing